DOWNLOADS Condensed financial statements Full year 2018 - Q3 2021 XLSX, 329.6 KB CURRENT FINANCIAL KEY FIGURES (9M 2021) Results: 9M 2021 9M 2020 9M 21|20 in % Revenues from contracts with customers T€ 9M 2021 430,963 9M 2020 360,414 9M 21|20 in % 20 R&D expenses T€ 9M 2021 (53,472) 9M 2020 (46,077) 9M 21|20 in % 16 Operating result T€ 9M 2021 26,053 9M 2020 35,286 9M 21|20 in % (26) Adjusted Group EBITDA1) T€ 9M 2021 70,086 9M 2020 76,942 9M 21|20 in % (9) Net income T€ 9M 2021 246,988 9M 2020 5,849 9M 21|20 in % >100 9M 2021 9M 2020 9M 21|20 in % Balance sheet data: 9M 2021 9M 2020 9M 21|20 in % Total stockholders' equity T€ 9M 2021 992,679 9M 2020 472,772 9M 21|20 in % >100 Capital expenditure2) T€ 9M 2021 (100,183) 9M 2020 (55,348) 9M 21|20 in % 80 Liquidity3) T€ 9M 2021 417,576 9M 2020 255,324 9M 21|20 in % 63 Balance sheet total T€ 9M 2021 1,767,849 9M 2020 1,169,671 9M 21|20 in % 51 Operating cash flow T€ 9M 2021 61,602 9M 2020 20,784 9M 21|20 in % >100 9M 2021 9M 2020 9M 21|20 in % Personnel data: 9M 2021 9M 2020 9M 21|20 in % Employees as of 30 September 9M 2021 4,081 9M 2020 3,572 9M 21|20 in % 14 9M 2021 9M 2020 9M 21|20 in % Per share: 9M 2021 9M 2020 9M 21|20 in % Result (basic/diluted) € 9M 2021 1.50/1.50 9M 2020 0.04/0.04 9M 21|20 in % >100 MULTIPLE-YEAR OVERVIEW OF RESULTS OF OPERATIONS AND BALANCE SHEET Results of operations: 2016 20171) 2018 2019 2020 Revenues from contracts with customers 2016 164,507 20171) 263,765 2018 375,405 2019 446,437 2020 500,925 Costs of revenue 2016 (105,953) 20171) (181,965) 2018 (263,389) 2019 (313,546) 2020 (375,181) Gross profit 2016 58,554 20171) 81,800 2018 112,016 2019 132,891 2020 125,743 R&D expenses 2016 (18,108) 20171) (17,614) 2018 (35,619) 2019 (58,432) 2020 (63,945) SG&A expenses 2016 (27,013) 20171) (42,383) 2018 (57,012) 2019 (66,546) 2020 (77,238) Impairment of goodwill (net) 2016 (3,989) 20171) - 2018 - 2019 (1,647) 2020 - Impairment of intangible assets (net) 2016 (1,417) 20171) (1,180) 2018 (4,364) 2019 (10,272) 2020 (3,244) Income from bargain purchaise 2016 - 20171) - 2018 15,400 2019 - 2020 - Other Operating income (and expenses), net 2016 23,315 20171) 16,104 2018 47,042 2019 66,600 2020 67,207 Operating result 2016 31,342 20171) 36,727 2018 77,463 2019 62,594 2020 48,523 Non-operating income and (expenses), net 2016 1,608 20171) (11,162) 2018 (5,464) 2019 (6,032) 2020 (22,716) Profit (loss) before taxes 2016 32,950 20171) 25,656 2018 71,999 2019 56,562 2020 25,807 Tax income (expense) 2016 (6,111) 20171) (2,347) 2018 12,057 2019 (19,334) 2020 (19,555) Net income 2016 26,839 20171) 23,218 2018 84,056 2019 37,228 2020 6,252 2016 20171) 2018 2019 2020 Balance sheet data: 2016 20171) 2018 2019 2020 Cash, cash equivalents and investments 2016 126,270 20171) 91,156 2018 149,449 2019 320,022 2020 481,930 Trade accounts receivable incl. related parties 2016 28,300 20171) 46,113 2018 48,030 2019 83,616 2020 87,896 Inventories 2016 4,305 20171) 5,568 2018 5,660 2019 10,749 2020 13,585 Deferred tax assets 2016 10,462 20171) 19,233 2018 43,329 2019 34,330 2020 24,950 Property, plant and equipment 2016 43,018 20171) 76,069 2018 90,519 2019 239,229 2020 337,297 Intangible assets, excluding goodwill 2016 33,267 20171) 135,033 2018 122,989 2019 116,994 2020 98,036 Goodwill 2016 85,688 20171) 220,447 2018 220,791 2019 255,919 2020 247,370 Other assets2) 2016 22,797 20171) 72,856 2018 91,116 2019 120,053 2020 171,831 Total assets 2016 354,107 20171) 666,475 2018 771,883 2019 1,180,912 2020 1,462,895 Loans and finance leases 2016 28,827 20171) 189,928 2018 114,465 2019 463,099 2020 491,965 Trade accounts payable 2016 11,997 20171) 26,078 2018 31,137 2019 31,319 2020 42,549 Provisions 2016 30,340 20171) 39,132 2018 47,965 2019 55,688 2020 64,747 Contract liabilities 2016 56,484 20171) 44,844 2018 112,228 2019 104,852 2020 88,914 Other liabilities3) 2016 12,523 20171) 34,578 2018 41,208 2019 48,925 2020 51,874 Total stockholders' equity 2016 213,936 20171) 331,915 2018 424,880 2019 477,029 2020 722,846 Total liabilities and stockholders' equity 2016 354,107 20171) 666,475 2018 771,883 2019 1,180,912 2020 1,462,895 2016 20171) 2018 2019 2020 Personnel data: 2016 20171) 2018 2019 2020 Employees as of 31 December 2016 1,238 20171) 2,178 2018 2,617 2019 3,030 2020 3,572 2016 20171) 2018 2019 2020 Per share (in €): 2016 20171) 2018 2019 2020 Result (basic/diluted) 2016 0.20/0.20 20171) 0.16/0.17 2018 0.56/0.57 2019 0.25/0.25 2020 0.04/0.04 1) 2017 restated for IFRS 15 and modified by the effect of the finalisation of Aptuit's purchase price allocation in 2018 in accordance with IFRS 3, see Note 4 in the Notes 2) Consist of tax receivables, deferred tax assets, contract assets, prepaid expenses, equity investments, other long-term investments and other financial assets 3) Consist of current and deferred tax, deferred income and other financial and non-financial liabilities GUIDANCE 2021 Group revenues from contracts with customers Guidance 2021 € 550-570 m1) Actual 2020 € 500.9 m Unpartnered R&D expenses Guidance 2021 € 50-60 m Actual 2020 € 46.4 m Adjusted Group EBITDA3) Guidance 2021 € 105-120 m2) Actual 2020 € 123.1 m 1) At unchanged exchange rates against the average rate for 2020, this forecast range would be approximately € 565 m to € 585 m, ceteris paribus. 2) At unchanged exchange rates against the average rate for 2020, this forecast range would be around € 115 m to € 130 m, ceteris paribus. 3) EBITDA is defined as earnings before interest, taxes, depreciation and amortisation of intangibles. Adjusted EBITDA excludes impairments on goodwill, other intangible and tangible assets, changes in contingent considerations as well as the total non-operating result MID-TERM TARGETS BY 2025 Group revenues from contracts with customers Mid-term targets by 2025 > € 1,000 m Actual 2020 € 500.9 m Unpartnered R&D expenses Mid-term targets by 2025 > € 100 m Actual 2020 € 46.4 m Adjusted Group EBITDA Mid-term targets by 2025 ≥ € 300 m Actual 2020 € 123.1 m DOWNLOADS Condensed financial statements Full year 2018 - Q3 2021 XLSX, 329.6 KB Multiple-year overview P&L 2016-2020 XLSX, 30.8 KB Multiple-year overview balance sheet 2016-2020 XLSX, 28.9 KB Latest consolidated Analyst Consensus (H1 2021) XLSX, 55.0 KB TOP RSS Twitter LinkedIn EVOTEC @Evotec A new approach to off-the-shelf cancer vaccines - https://t.co/4Re4h5FDGx | Our latest blog details Dendritic Cells… https://t.co/xB7m0D5k8k 02:08 PM - 24 NOVEMBER 2021